In this simple, sensitive radioimmunoassay (RIA) of atrial natriuretic polypeptide (hANP) in human plasma, nonspecific interference is minimized by deproteinizing the plasma by heat treatment at 85 #{176}C for 10 mm. We directly measure ahANP in the supernates by AlA, with use of antiserum that recognizes the N-terminal region of a-hANP. The minimal detectable value was 0.4 pg per tube. The intra-assay CV was 6.6% (n = 8). The mean concentration of hANP in plasma of 54 healthy volunteers was 41 (SD 29) ng/L. Concentrations of hANP in plasma increased after saline infusion and high salt intake for one week in patients with essential hypertension. High concentrations were also measured in patients with renal failure and congestive heart failure. This method, which requires no extraction or purification with column chromatography, is especially useful for simultaneous measurement of several samples.
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In this simple, sensitive radioimmunoassay (RIA) of atrial natriuretic polypeptide (hANP) in human plasma, nonspecific interference is minimized by deproteinizing the plasma by heat treatment at 85 #{176}C for 10 mm. We directly measure ahANP in the supernates by AlA, with use of antiserum that recognizes the N-terminal region of a-hANP. The minimal detectable value was 0.4 pg per tube. The intra-assay CV was 6.6% (n = 8). The mean concentration of hANP in plasma of 54 healthy volunteers was 41 (SD 29) ng/L. Concentrations of hANP in plasma increased after saline infusion and high salt intake for one week in patients with essential hypertension. High concentrations were also measured in patients with renal failure and congestive heart failure. This method, which requires no extraction or purification with column chromatography, is especially useful for simultaneous measurement of several samples.
Additional Keyphrases: hypertension renal failure heart disease . sample treatment with chromatographic cartridges compared RIA of hANP in plasma has been widely used to investigate the physiological and pathophysiological roles of newly discovered a-hANP (J).3 To determine the concentrations of a-hANP in plasma, several investigators (2-4) have used a purification method involving Sep-Pak C18 cartridges. However, this extraction method is very complicated and timeconsuming and requires a relatively large sample volume; moreover, the analytical recovery from each column is not always the same. Therefore, methods involving such column purification procedures are not suitable as routine clinical assays for use with large numbers of samples. Here we report a simple, sensitive RIA for plasma a-hANP that includes no column-chromatographic steps. a-hANP-free plasma. Washed charcoal beads were packed into a 2 x 40 cm glass column, and washed again with 0.5 L of de-ionized water. We then passed 300 mL of pooled plasma from normal subjects through the column. The first 60 mL of effluent was discarded and the subsequent fractions were pooled. We used this a-hANP-free plasma as diluent in preparing a standard curve for RIA.
Materials and Methods

Materials
Heat treatment
of human plasma. We mixed 500 pL of human plasma with an equal volume of 0.1 moh/L acetic acid solution, heated the mixture at 85#{176}C for 10 mm, and then centrifuged at 2200 x g for 10 mm. We assayed 100 .iL of each supernate. For the standard curve we mixed 500 iL of a-hANP-free plasma with 500 L of each standard solution, then proceeded as with the samples.
Radioiodination and purification. We radioiodinated ahANP by the conventional Chloramine T method (5). We purified the radioiodunated mixture by applying it to a 0.9 x 50 cm column of Sephadex G-50 (Pharmacia Japan, Tokyo, Japan), and eluting with 1 mol/L acetic acid solution. After testing the immunological activity of the material corresponding to the radioactive peaks, we pooled the fractions and stored them in 1 mol/L acetic acid solution at -20 #{176}C until use. The specific activity of the product was approximately 1500 Ci/g. For assay, 'I-labeled a-hANP was diluted with zero standard solution.
Antiserum.
We emulsified 600 of a-hANP conjugated with BSA in 9 mL of isotonic saline with 9 mL of complete Freund's adjuvant, then injected the mixture into six New Zealand White rabbits at four-week intervals. After six months, usable antiserum was obtained. The antiserum (ANP-2) we used in the assay was selected after evaluating titer and specificity. In the RIA, we used 100 pL of antiserum diluted 108 000-fold. Antiserum to a-hAN?, for use as a control antibody, was purchased from Peninsula Co., Belmont, CA. It was diluted with phosphate buffer (50 mmol/L, pH 8.6) containing 1 g of NaN3, 5 g of BSA, and 1 mL of Triton X-100 per liter.
RIA assay procedure. We mixed 100 uL of zero standard solution, 100 tL of heat-treated human plasma or standard solution, 100 zL of 'I-labe1ed a-hAN?, 100 ML of the diluted antiserum, and 100 pL of R-IgG dissolved in the phosphate buffer mixture, and incubated overnight at 4#{176}C. Then we added 100 pL of goat antiserum to R-IgG, diluted 20-fold in the phosphate buffer mixture, and incubated at 4#{176}C for 2 h. After incubation, the assay mixtures were centrifuged (2200 x g, 4#{176}C, 30 mm). The supernates were decanted, and the radioactivity of the precipitates was measured in a well-type gamma counter.
Extraction by Sep-Pak C18. We used Sep-Pak C18 cartridges treated to extract hANP from human plasma by the method of Miyata et al. (1 mL/fr) Fig. 1 (1 g/L) and aprotinin (500 mt. unitJL), then centrifuged (2200 x g, 4#{176}C, 30 mm). The resulting plasma samples were either promptly assayed or stored at -20 #{176}C until assay.
Results
Cross reactivity of antiserum. We examined the cross reactivity of our antiserum (ANP-2) and Peninsula antibody with 10 different a-hANP fragments and a-rANP (Table 1) . Removing three amino acids from the N-terminal [a-hAN? (4-28)] did not significantly decrease cross reactivity, but removing four amino acids at the N-terminal [a-hANP (5-28)] significantly decreased cross reactivity. Our antiserum did not react with the fragment missing six amino acids at the N-terminal [a-hANP (7-28)]. These data (Table 1) show that our antiserum apparently recognizes only the N-terminal amino acid sequence of a-hANP, whereas the Peninsula antiserum reacts with both the N-terminal and the Cterminal amino acids.
Effect of heat treatment on a-h.ANP. We mixed a-hANP solutions (125, 250, 500, 1000, and 10000 ng/L in zero standard solution) with equivalent volumes of a-hANP-free plasma. After processing these samples by heat treatment and centrifugation, we assayed hANP values in 100-pL portions of the supernates.
On average, 111% of the expected value was measured, as shown in Table 2 .
Chromatography of a-hANP beftre and after heat treatment. We added 150 ng of a-hAN? to 3 mL of pooled plasma containing aprotinin (1500000 int. units), then applied 1 mL of this to a 1.5 x 4.5 cm column of Sephadex G-50. We eluted a-hAN? with another phosphate buffer mixture (50 mmol/L, plus 9 g of NaC1, 1 g of BSA, and 500 int. units of aprotinin per liter, pH 7.5) at a flow rate of 30 mL/h, and collected 1-mL fractions. We measured the concentration of a-hANP in each fraction by RIA. The total a-hANP collected in all fractions was 57 ng therefore, the yield of a-hANP was 117%. Another 1 mL of the pooled plasma containing 50 ng of a.hANP was mixed with 1 mL of 0.1 mob'L acetic acid solution and heated as described above. After centrifugation, we applied 1 mL of the supernate to the same column, and similarly determined the concentration of a-hANP in each fraction eluted. The total a-hAN? in all fractions was 25.5 ng for a total yield of 102%. We observed no significant differences in the elution pattern and total yield of a-hANP in plasma before and after heat treatment (Figure 1) .
Analytical variables. Figure 2 shows the reproducibility of the standard curve. The smallest amount of a-hAN? distinguishable from zero with 95% confidence was 0.4 pg per tube. The coefficient of intra-assay variance (n = 8) was 6.6% (average for four control plasmas). Average analytical recovery of 100, 200, and 400 ng of a-hAN? per liter, added to three plasma samples, was 97.4%. Twofold serial-dilutions of four samples with a-hANP-free plasma gave a good linear response to dilution. 
Discussion
Recently, many RIAs for hANP have been reported that are direct assays or extraction methods involving a Sep-Pak C18 column. Direct assays are believed to yield higher values because of nonspecific effects of plasma protein (6). However, Marumo et al. (7) reported a direct assay involving a sensitive and specific antibody and reasonable normal values: 32 (SD 12) ng/L (range 10-60 ng/L). Direct assays like this are, however, not considered possible when either commercially available antibody or our antibody is used. Therefore, many investigators must use the Sep-Pak C18 column method to eliminate nonspecific effects of plasma protein, a method that is very complicated and unsuited for assaying many samples concurrently. Furthermore, analytical recoveries are not consistent. Values for plasma hANP obtained by the heat-treatment method described here were equivalent to and correlated well with those obtained by the column method. Analytical recoveries of a-bANP were complete before and after the described heat treatment of plasma samples. The chromatograms of a-hANP before and after heat treatment were identical. Evidently the present method deproteinizes the plasma so that the column step can be eliminated. Use of the heat treatment method results in reproducible values, and many samples can be assayed at the same time. Our antiserum recognizes the N-terminal region, and values for hANP in plasma of normal men by our method were in a range comparable with those previously reported by the column method. Furthermore, using our method, we observed the expected (8, 9) increase in plasma hANP after saline infusion or high salt intake. These results help validate our method. The slight increase in hANP in plasma of patients with essential hypertension, the increased values in patients with congestive heart failure or renal failure, and the change in values before and after hemodialysis in patients with renal failure who were on chronic hemodialysis-all these observations are in good agreement with previous reports (10-14) . These results show that the hANP in the supernate after heat treatment, as assayed with our method, is mainly a-hANP.
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